Home
Login
Help
Search this site:
Registered Trials
By recruitment status
By sponsor
By registration date
Advanced search for trials
Registration process
To register a trial
Sponsor registration form
RPCEC trial registration Data Set
To update a registered trial
To disclosure the results of registered trial
Home
|
Phyisician Led CIMAvax-EGF lung biomarkers
View current
Revisions
List all revisions
View
Compare to current
11 March 2021 - 10:01pm
by Gladys
24 March 2023 - 8:24am
by Gladys
Changes to
Record Verification Date
-
2021/03/
11
+
2021/03/
15
Changes to
Next update date
-
2022/03/
11
+
2022/03/
15
Revision of 24 March 2023 - 8:24am:
Phyisician Led CIMAvax-EGF lung biomarkers
General information
Section to complete general information about the trial: scientific and public title, protocol identifiers, sponsors and Source(s) of Monetary or Material Support.
Acronym of Public Title:
CIMAvax-EGF vaccine lung Biomarkers
Scientific title:
Evaluation of biomarkers associated with clinical efficacy of CIMAvax-EGF® vaccine in patients with advanced stages (IIIB and IV) of non-small cell lung cancer who have been treated with this therapy. Physician Led
Acronym of Scientific Title:
CIMAvax-EGF vaccine lung Biomarkers
Secondary indentifying numbers:
FL-EC-0026
Issuing authority of the secondary identifying numbers:
Center of Molecular Immunology (CIM)
Primary sponsor:
Center of Molecular Immunology (CIM)
Secondary sponsor:
Innovative Immunotherapy Alliance (IIA)
Source(s) of monetary or material support:
Center of Molecular Immunology, Cuban Ministry of Public Health (MINSAP), Innovative Immunotherapy Alliance (IIA)
Authorization for beginning
Section to complete information about the regulatory approval of clinical trial: regulatory agency name, approval date and reference number in the agency.
Regulatory instance to authorize the initiation of the study:
Only approved by Ethics Committees
Principal investigator
Section to complete information about Email address, telephone number and postal address of the Principal Investigator.
First name:
Ramon
Midle name:
Alberto
Last name:
Ortiz Carrodeguas
Medical Specialty :
MD, First degree specialist in Oncology
Affiliation:
“Celestino Hernandez Robau” Hospital
Postal address:
Cuba No. 564 entre Barcelona y Hospital
City:
Santa Clara, Villa Clara
Country:
Cuba
Zip Code:
50100
Telephone:
+53-42271202
+53-42279442
Email address:
raortizcarrodeguas@gmail.com
Clinical sites to participate
Section to complete the data related to the clinical sites involved in the trial: site and responsible investigator for every site.
Countries of recruitment:
Cuba
Clinical sites:
Pinar del Rio, “III Congreso” Hospital, Dr. Liudmila Herrera Rodriguez, MD, Second Degree specialist in Oncology
Matanzas, “Faustino Perez” Hospital, Dra. Kirenia Camacho Sosa. MD, Second Degree specialist in Oncology
Recruitment status
Section to complete information about the recruitment status and the date of first enrolment subject
Recruitment status:
Pending
Date of first enrollment:
12/03/2021
Health condition and Intervention
Section to complete information about the primary medical condition(s) or problem(s) studied and, a characteristics of the intervention(s).
Health condition(s) or Problem(s) studied:
Advanced non small cell lung cancer
Health condition(s) code:
Carcinoma, Non-Small-Cell Lung
Carcinoma, Bronchogenic
Bronchial Neoplasms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Lung Diseases
Respiratory Tract Diseases
Intervention(s):
CIMAvax-EGF therapeutic vaccine, 2.4 mg by intramuscular route. Indication: induction stage, four weekly administrations every 14 days, maintenance stage, administration every 28 days until the patient's clinical conditions allow. Prior to the first dose of the vaccine, immunomodulatory dose cyclophosphamide (200 mg / m2, intravenous) will be administered.
Intervention code:
Biomarkers, Tumor
Immunotherapy, Active
Epidermal Growth Factor
Cyclophosphamide
Injections, Intramuscular
Administration, Intravenous
Intervention keyword:
CIMAvax-EGF
Outcomes and Timepoint
Section to complete information about primary and secondary outcomes including. It includes the metric or method of measurement used and, the time point for every outcome.
Primary outcome(s):
1-Expression of biomarkers in paraffin biopsies or cytology (EGFR mutations, KRAS mutations, BRAF mutations by molecular biology) and (ALK, ROS1 and PD-L1 expression by immunohistochemistry). Measurement time: At diagnosis of the disease 2-EGFR mutations in liquid biopsies (KRAS and BRAF mutations by molecular biology (cfDNA)). Measurement time: during the maintenance phase with CIMAvax-EGF, every 6 months or 1 year after the previous extraction; for a period of 2 years. 3-Genetic profile of the nasal epithelium by brushing (Genetic Profile). Measurement time: during the maintenance phase with CIMAvax-EGF, every 6 months or 1 year after the previous extraction; for a period of 2 years. 4-EGFR cytosine and growth factor concentration (EGF concentration, TGF alpha concentration, IL8 concentration, IL4 concentration, IL 13 concentration, other cytosine concentration) Measurement time: during the maintenance phase with CIMAvax-EGF, every 6 months or 1 year after the previous extraction; for a period of 2 years. 5- Antibody response vs EGF (Titer of Ab Anti EGF). Measurement time: during the maintenance phase with CIMAvax-EGF, every 6 months or 1 year after the previous extraction; for a period of 2 years. 6- Percentage of lymphocyte subpopulations in circulating peripheral mononuclear cells (PBMC). (% CD8 naive T,% CD8 effector cells,% CD4 naive T cells,% CD4 effector T cells,% th17 T cells,% Tregs cells,% CD19 + B cells,% CD4 + T cells,% CD8 + T cells,% CD8 + CD28 T cells -, CD4/CD8 index) Measurement time: during the maintenance phase with CIMAvax-EGF, every 6 months or 1 year after the previous extraction; for a period of 2 years. 7- Global survival time (Time between the begining of CIMAvax-EGF treatment and the date of death of the patient or date of last news). Measurement time: At baseline and, monthly for 2 years. 8-Treatment evaluation for progression (Complete Response, Partial Response, Stable Disease, Progression Disease): Measurement time: at baseline and, every 6 months for 2 years.
Key secondary outcomes:
Not applicable
Selection criterias
Section to complete information about the inclusion and exclusion criteria for participant selection, including age and gender.
Gender:
Male/Female
Minimum age:
18 years
Maximum age:
None
Inclusion criteria:
1. Patients of any sex and age greater than or equal to 18 years. 2. Patients who have signed the informed consent for the research. 3. Patients who meet the diagnostic criteria. 4. Patients with at least stable disease after 1st line chemotherapy, who have been included in clinical trials with the CIMAvax-EGF vaccine or have been treated as part of routine medical practice. 5. Patients who have completed the induction stage with the CIMAvax-EGF® vaccine and are receiving the vaccine as maintenance therapy. 6. Patients with clinical status criteria (ECOG) from 0 to 2
Exclusion criteria:
1. Patients of childbearing potential who are not using adequate contraception (intrauterine devices, hormonal contraceptives, barrier methods or tubal ligation). In the case of males (vasectomy, use of condoms) while the treatment lasts 2. Pregnant, lactating or postpartum patients. 3. Patients with uncontrolled intercurrent illnesses including, but not limited to: active infections, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, diabetes mellitus, arterial hypertension and psychiatric illnesses that imply the incompetence of the subject. 4. Patients with brain metastases. 5. Patients with acute allergic states or history of severe allergic reactions.
Type of population:
Adults
Type of participant:
Patients
Study design
Section to complete information about the characteristics of the study design.
Type study:
Interventional
Purpose:
Other
Other purpose:
Evaluation of biomarkers of efficacy of CIMAvax-EGF vaccine
Allocation:
N/A: single arm study
Masking:
Open
Control group:
Uncontrolled
Study design:
Single group
Phase:
N/A
Target sample size:
140
Contact for public queries
Section to complete information about Email address, telephone number and postal address of the contact who will respond to general queries, including information about current recruitment status
First Name:
Geidy
Last Name:
Lorenzo Monteagudo
Specialty:
BSc. in Pharmaceutical Sciences
Affiliation:
Center of Molecular Immunology
Postal Address:
Calle 216 Esquina 15, Atabey, Playa.
City:
Havana
Country:
Cuba
Zip Code:
16040, Box 11600
Telephone:
+53-53806987
Email :
geydi@cim.sld.cu
geidylm72@gmail.com
Contact for scientific queries
Section to complete information about Email address, telephone number and postal address of the contact who will respond to scientific queries.
First Name:
Zaima
Last Name:
Mazorra Herrera
Specialty:
DrC. in Biological Sciences
Affiliation:
Innovative Immunotherapy Allience (IIA)
Postal Address:
Calle 216 Esquina 15, Atabey, Playa
City:
Havana
Country:
Cuba
Zip Code:
16040, Box 11600
Telephone:
+53-72717933 ext 3391
Email :
zaima1972@gmail.com
Data Sharing
Section to complete the data related to the data sharing plan.
Data sharing plan:
No
Research Ethics Committees
Section to complete the data related to the review ethics committees.
Name of Research Ethics Committees:
III Congreso Hospital
Celestino Hernandez Hospital
Faustino Perez Hospital
Status of evaluation:
Approved
In review
In review
Status of evaluation date of Ethic Committee:
22/01/2021
05/01/2021
01/03/2021
Postal address of Ethic Committee :
Calle 2da y 26 de Julio. Pinar del Rio. ZC: 20100, Cuba
Cuba No. 564 entre Barcelona y Hospital. Santa Clara, Villa Clara. ZC:50100, Cuba
Carretera Central Km 101. Matanzas. ZC:40100, Cuba
Telephone:
+53-48762473
+53-42279401
+53-4547016, 256001, 256002
Email:
liudmyhr@infomed.sld.cu
direccion@hchr.vcl.sld.cu
bibliotfaustinop.mtz@infomed.sld.cu
About study completion
Section to complete the data related to the study completion.
Study completion date:
12/03/2024
Date of available results:
12/06/2024
Date of first publication:
12/12/2024
Registration and Update
Section to complete information about the name of Primary Registry, date of registration and the unique ID number assigned by the registry (RPCEC).
Primary registry:
RPCEC
Unique ID number:
RPCEC00000355
Date of Registration in Primary Registry:
11/03/2021
Record Verification Date:
2021/03/15
Next update date:
2022/03/15
Link to the spanish version:
Click here
About the RPCEC
Structure and governance
Policy
Publications
Awards
Communications
News
Useful resources
Fundamentals of the registry
References of clinical trials
Cuban regulations
Other registries
International Clinical Trials Registry Platform